Geode Capital Management LLC Purchases 29,514 Shares of Protara Therapeutics, Inc. (NASDAQ:TARA)

Geode Capital Management LLC grew its stake in shares of Protara Therapeutics, Inc. (NASDAQ:TARA) by 21.0% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 170,040 shares of the company’s stock after buying an additional 29,514 shares during the quarter. Geode Capital Management LLC owned 0.82% of Protara Therapeutics worth $311,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. Renaissance Technologies LLC raised its position in Protara Therapeutics by 77.8% in the 2nd quarter. Renaissance Technologies LLC now owns 150,400 shares of the company’s stock worth $313,000 after purchasing an additional 65,800 shares during the period. Marshall Wace LLP bought a new stake in Protara Therapeutics during the second quarter worth about $161,000. Armistice Capital LLC purchased a new position in Protara Therapeutics in the second quarter worth about $1,082,000. CVI Holdings LLC purchased a new position in Protara Therapeutics in the second quarter worth about $630,000. Finally, Oppenheimer & Co. Inc. raised its holdings in Protara Therapeutics by 40.8% in the third quarter. Oppenheimer & Co. Inc. now owns 179,125 shares of the company’s stock worth $328,000 after buying an additional 51,944 shares during the last quarter. Hedge funds and other institutional investors own 38.13% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. Guggenheim reissued a “buy” rating and set a $20.00 price objective on shares of Protara Therapeutics in a report on Friday, December 6th. HC Wainwright reiterated a “buy” rating and issued a $23.00 price target on shares of Protara Therapeutics in a research report on Friday, December 6th.

Protara Therapeutics Stock Down 4.5 %

Protara Therapeutics stock opened at $5.31 on Tuesday. The company has a market cap of $109.55 million, a price-to-earnings ratio of -1.88 and a beta of 1.56. The firm’s fifty day moving average is $4.34 and its 200 day moving average is $2.85. Protara Therapeutics, Inc. has a 52-week low of $1.60 and a 52-week high of $10.48.

Protara Therapeutics (NASDAQ:TARA) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.50) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.50). On average, equities research analysts anticipate that Protara Therapeutics, Inc. will post -2.99 earnings per share for the current fiscal year.

Protara Therapeutics Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.